Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial

Volume: 32, Issue: 4, Pages: 552 - 559
Published: Apr 1, 2021
Abstract
•There are limited data regarding optimal treatment regimens for patients with relapsed/refractory PTCL.•The copanlisib/gemcitabine combination demonstrates promising efficacy in relapsed/refractory PTCL, particularly in those with angioimmunoblastic T-cell lymphoma.•TSC2 mutation occurred exclusively in responders and may have potential as a response marker to combination therapy. BackgroundCurrent treatment options for peripheral T-cell...
Paper Details
Title
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial
Published Date
Apr 1, 2021
Volume
32
Issue
4
Pages
552 - 559
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.